Bonaventura Clotet
Bonaventura Clotet
Director irsiCaixa AIDS Research Institute
Verified email at
TitleCited byYear
Combination antiretroviral therapy and the risk of myocardial infarction
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
Y Cao, L Qin, L Zhang, J Safrit, DD Ho
New England Journal of Medicine 332 (4), 201-208, 1995
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study
R Weber, CA Sabin, N Friis-Moller, P Reiss, WM El-Sadr, O Kirk, F Dabis, ...
Arch Intern Med 166 (15), 1632-41, 2006
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
Raltegravir with optimized background therapy for resistant HIV-1 infection
RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ...
New England Journal of Medicine 359 (4), 339-354, 2008
Maraviroc for previously treated patients with R5 HIV-1 infection
RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ...
New England Journal of Medicine 359 (14), 1429-1441, 2008
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society–USA Panel
MS Hirsch, F Brun-Vézinet, TD Richard, SM Hammer, VA Johnson, ...
Jama 283 (18), 2417-2426, 2000
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
A Lazzarin, B Clotet, D Cooper, J Reynes, K Arastéh, M Nelson, ...
New England Journal of Medicine 348 (22), 2186-2195, 2003
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management
MS Hirsch, B Conway, TD Richard, VA Johnson, F Brun-Vézinet, B Clotet, ...
Jama 279 (24), 1984-1991, 1998
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
MS Hirsch, F Brun-Vézinet, B Clotet, B Conway, DR Kuritzkes, ...
Clinical Infectious Diseases 37 (1), 113-128, 2003
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
A Lazzarin, T Campbell, B Clotet, M Johnson, C Katlama, A Moll, ...
The Lancet 370 (9581), 39-48, 2007
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ...
New England Journal of Medicine 359 (4), 355-365, 2008
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two …
B Clotet, N Bellos, JM Molina, D Cooper, JC Goffard, A Lazzarin, ...
The Lancet 369 (9568), 1169-1178, 2007
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
MS Hirsch, HF Günthard, JM Schapiro, FB Vézinet, B Clotet, SM Hammer, ...
Clinical Infectious Diseases 47 (2), 266-285, 2008
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
MJ Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460, 2010
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy
AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ...
Jama 316 (2), 171-181, 2016
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial
C Tural, L Ruiz, C Holtzer, J Schapiro, P Viciana, J González, P Domingo, ...
Aids 16 (2), 209-218, 2002
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 …
CB Hicks, P Cahn, DA Cooper, SL Walmsley, C Katlama, B Clotet, ...
The Lancet 368 (9534), 466-475, 2006
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3 …
CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie, MA Johnson, ...
The Lancet 378 (9787), 229-237, 2011
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
MR Nelson, C Katlama, JS Montaner, DA Cooper, B Gazzard, B Clotet, ...
Aids 21 (10), 1273-1281, 2007
The system can't perform the operation now. Try again later.
Articles 1–20